A carregar...
Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma
More than 50% of human cancers harbor TP53 mutations and increased expression of Mouse double minute 2 homolog (MDM2), which contribute to cancer progression and drug resistance. Renal cell carcinoma (RCC) has an unusually high incidence of wild-type p53, with a mutation rate of less than 4%. MDM2 i...
Na minha lista:
| Publicado no: | Cells |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7349864/ https://ncbi.nlm.nih.gov/pubmed/32560270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9061475 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|